


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+4.16%
-0.88%
-6.48%
-3.96%
+11.82%
LASR
nLIGHT
$43.83
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value
LASR Price Performance
$34.66 (+26.46%)
$31.81 (+37.79%)
$28.05 (+56.26%)
$11.17 (+292.39%)
LASR has Extreme risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

LASR overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
LASR Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
LASR Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
LASR
nLIGHT
43.83
+1.53%
BSAC
Banco Santander -
32.26
-2.36%
LAW
CS Disco
6.82
+1.49%
QUIK
QuickLogic
7.78
-0.89%
AIRS
AirSculpt Technologies
2.22
-3.06%
What is LASR current stock price?
What are LASR stock strengths?
What is LASR Risk Level?
What is LASR market cap and volume?
What is LASR current Stock IQ?
Should I buy LASR stock right now?
Is LASR a Strong Buy right now?
What does a 'Strong Buy' rating mean for LASR?
What does a 'Strong Sell' rating mean for LASR?
What factors influence LASR's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+4.16%
-0.88%
-6.48%
-3.96%
+11.82%
LASR
nLIGHT
Current Price
$43.83
LASR Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value
Recently Viewed
LASR
nLIGHT
43.83
+1.53%
BSAC
Banco Santander -
32.26
-2.36%
LAW
CS Disco
6.82
+1.49%
QUIK
QuickLogic
7.78
-0.89%
AIRS
AirSculpt Technologies
2.22
-3.06%

LASR Price Performance
$34.66 (+26.46%)
$31.81 (+37.79%)
$28.05 (+56.26%)
$11.17 (+292.39%)
LASR Analysts Opinion
LASR Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
LASR Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
LASR Street Sentiment is extremely bullish and have positive views on the near-term outlook
LASR has Extreme risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

Average key support and resistance price levels
LASR Latest Analysis
Kaneka Medical America LLC Announces United States Launch of WaveSelect 1014 Guidewire. NEW YORK Jan. 13 2026 (GLOBE NEWSWIRE) -- a subsidiary company of innovating embolization coil technology for neurovascular therapies today announced the United States launch of the WaveSelectTM 1014 guidewire through an exclusive distribution agreement with Enlight Medical Ltd. Under the terms of the partnership Kaneka will hold exclusive rights to distribute Enlight'.s next-generation guidewire techno
Tue Jan 13, 2026
nLIGHT CEO Sells 31748 Shares as Company Reveals Q4 Revenue Topped Guidance. Key PointsThe president and CEO of nLIGHT sold 31748 shares of the company for a total transaction value of $1.19 million on Jan. 6.
Tue Jan 13, 2026
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio. Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and comorbidities in 1H 2026 and initiate new trials of WVE-007 as an add-on to incretin and as post-incretin maintenance in 2026
Mon Jan 12, 2026
Roth Capital Highlights nLIGHTs (LASR) Strategic Advantage in Directed Energy Lasers Fast-Tracking of Laser-Based Weaponry. nLIGHT Inc. (NASDAQ:LASR) is one of the hot tech stocks to invest in. On December 17 Roth Capital initiated coverage of nLight with a Buy rating and $44 price target. The firm highlighted nLIGHTs strategic advantage as a specialized provider of directed energy lasers. Roth MKM anticipates that a convergence of market forces will fast-track [….]
Fri Jan 9, 2026
Trump Greenlights 500% Tariff Plan To Choke Off Russian Oil Bought By China India And Brazil— Senate Vote Possible Next Week. President Sen. Graham following a meeting with the president on Wednesday announced that the Senate could vote on the new sanctions as early as next week. The bill would give Trump leverage to pressure countries such as China India and Brazil to stop buying discounted Russian oil that funds Russia'.s war in Ukraine stated Graham. “.This bill will allow President
Thu Jan 8, 2026
ARWR: Encouraging Early Data for Obesity Programs. By Business UpdateEncouraging Early Data for Obesity ProgramsOn January 6 2026 Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) announced preliminary results for the companys investigational treatments for obesity ARO-INHBE and ARO-ALK7. The company also held a webinar to discuss the results. The slides and the webinar can be accessed here. The data showed that ARO-INHBE both as a monotherapy and in combination with tirzepatide led to reductions in
Wed Jan 7, 2026
Constellation Gets Green Light For Nuclear Upgrade. ) shares are trading lower on Tuesday after the company announced a key regulatory milestone for its The firm said the United States Nuclear Regulatory Commission approved a License Amendment Request for a major digital upgrade at its Limerick Clean Energy Center marking a first-of-its-kind modernization at a United States nuclear plant.The NRC'.s decision greenlights Constellation'.s Digital Modernization Project at Limerick'.s con
Tue Jan 6, 2026
BEL BDL other defence stocks rally up to 3% ahead of DAC meeting to potentially unlock orders worth Rs 80000 cr . Friday brought a significant rise in defence stocks fueled by the upcoming Defence Acquisition Council meeting that is poised to greenlight substantial defence contracts totaling Rs 80000 crore. The spotlight will be on essential military technologies including airborne early warning systems and drones designed to fortify Indias defensive infrastructure and elevate domestic productio
Fri Dec 26, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
LASR Stock trends
LASR Stock performance
LASR Stock analysis
LASR investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.